Navigation Links
Transdermal HRT not cardioprotective in postmenopausal women with CAD ,,

Transdermal hormone replacement therapy (HRT) does not reduce the risk of cardiac events in postmenopausal women with existing coronary artery disease (CAD). In the PHASE trial (Papworth HRT Atherosclerosis Study), researchers randomized 255 postmenopausal women with angiographically proven coronary artery disease to receive either transdermal HRT--17-beta-estradiol with or without cyclic norethisterone--or no hormone replacement therapy. The women were followed for 4 years. Overall, 134 women received hormone replacement therapy. Of these, 58 had a previous hysterectomy. The other 121 women served as controls.

On intention-to-treat analysis, there was no statistical difference in the incidence of unstable angina requiring hospitalization, MI or premature death from heart disease in women receiving HRT and women not receiving the therapy. Respectively, the average event rates were 15.6 and 12.6 per 100 patient-years. Results from the PHASE study also seem to indicate an increased risk of thromboembolic complications, such as stroke, with HRT. This observation is supported by results from the HERS study, a randomized trial carried out in the US that included 3000 women, and was designed to assess the cardioprotective effect of combined HRT in women with documented CAD. It may therefore be appropriate that women with proven coronary artery disease should not commence HRT. Nevertheless, women receiving HRT for more than 2 years should continue.
'"/>




Page: 1

Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
2. Transdermal Vaccine Effective in Treating Alzheimers Disease in Mice
3. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
4. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
5. Enlarged waistline may predict atherogenesis for postmenopausal women
6. Research explains why postmenopausal women accumulate abdominal fat.
7. Testosterone Therapy can improve sexual function in postmenopausal women
8. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
9. Starvation in pregnant women can cause heart disease to their children
10. Brisk Walking lowers memory loss in women
11. Young womens woes

Post Your Comments:
(Date:11/25/2009)...aw definite conclusions, experts say, , ...tic patients with blocked coronary arteries, there...ar whether patients undergo bypass surgery or angi... , Bypass surgery has been the standard treatme...ase. However, less invasive approaches such as ang...
(Date:11/25/2009)...ms, study finds , , WEDNESDAY, Nov. 25 ...among the potential problems faced by long-term su... cisplatin-based chemotherapy, a new study has fou...eated for unilateral testicular cancer between 198...ducted from 1998 to 2002. , The researchers fou...
(Date:11/25/2009)...ghtYear ,, WASHINGTON,Nov.25/PRNewswire-USNew...issuedthe 4thAnnualReportCardonLungCancer .ThisRep...haldiseaseinthestateofGeorgia.LCA-GAisachapterofLu...edicatedexclusivelytopatientsupportandadvocacyforp... http://www.newscom.com/cgi-bin/prnh/20081016/LCAL...
(Date:11/25/2009)...r cells, study finds , , WEDNESDAY, Nov.... in a fingernail-size implant eliminated melanoma ...od uses polymer disks, 8.5 millimeters in diameter... implanted under the skin to reprogram the immune ...ientists who developed the implant predicted that ...
(Date:11/25/2009)...emier resource for life science careers and inform...™ Hotbed Campaign this morning. , ...2009 -- BioSpace.com, the premier resource for lif...ird edition of the BioForest™ Hotbed Campaig... a promotional effort highlighting biotechnology, ...
Breaking Medicine News(10 mins):Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2
...rch 04, 2009 A new study appearing in Journal of...lder women who reported taking daily naps had a si...the study are in contrast to a number of prior stu...er a 7-year period. Women who reported napping dai...
...provide an accurate indication of the severity of ...threat in South-East Asia, the Pacific and Europe,... Since the biomarkers can be easily detected and m...ny biological factors such as cytokines and chemok...
...man resources to retire after more than 28 years o...d Company (NYSE: LLY ) today announced that Anth... human resources, will be retiring from his positi...d at a later date. , , Dr. Murphy first joined ...
...d help explain disparities in care, experts sugges...-- The level of personal connection between a pati...esearchers have found. , Because health care is o...g relationship with a specific doctor are more lik...
...ire-FirstCall/ - CRH Medical Corporation (CRM:TSX-...teps toward being cash flow positive in 2009. , Th...cian compensation. The compensation for the physic...ompany to limit its expenses and to operate its ce...
...vide a Collaborative Health Care Solution for the ... In an effort to help stem the ever-rising costs ... helping their workers achieve and maintain health...solution designed specifically for the Connecticut...
Other Medicine News:Health News:Biomarkers detected for Chikungunya fever 2Health News:Biomarkers detected for Chikungunya fever 3Health News:Lilly's Anthony Murphy Announces Retirement 2Health News:Doc-Patient Relationship May Be Key to Quality 2Health News:CRH Medical focuses on profitability in 2009 2Health News:Anthem Blue Cross and Blue Shield in Connecticut Launches Innovative New Program for Cities and Towns 2Health News:Anthem Blue Cross and Blue Shield in Connecticut Launches Innovative New Program for Cities and Towns 3
(Date:11/25/2009)...TrendsResearchGroup,Inc.releasedWave1ofits Launch...asesyndicatedmarketresearchprojecttrackingthelaunc...hthroughthefirstsixmonthsofavailability.Eachwaveof...ueDermatologistsandqualitativeinformationfromasubs...lestouse,typicalpatienttypes,productperceptions,pr...
(Date:11/25/2009)...re/--RegadoBiosciences,aprivatelyheldcompanyleadin...ontrolagents,announcedthatDavidMazzo,PhD,CEOandPre...HealthCareConferenceattheNewYorkPalaceHotelinNewYo...ST)onTuesday,December1andwillincludeanoverviewofth...program,theanticoagulantsystem,REG1.Thehealthcarei...
(Date:11/25/2009)...ire/--SwissrayInternational,Inc.aleadingmanufactur...edtodaythatitsoperationshavebeenacquiredbyaprivate...ay,smedicalimagingbrand.Theacquisitionincludedalla...nventory.After25yearsofsuccessandgrowthSwissrayisn...mentswithstableandsteadygrowth. ,, "Swissrayhas...
Breaking Medicine Technology:Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Swissray International Announces New Ownership 2Parameter Generation and Control Launches New Catalog 26quot 3BPharmaceutical Stability Solutions 26quot 3B 14328 1Parameter Generation and Control Launches New Catalog 26quot 3BPharmaceutical Stability Solutions 26quot 3B 14328 2Major Central Florida Label Printer Creates On Line Label Superstore Catering To Users Of Blank Labels For Thermal Printers 58739 1Major Central Florida Label Printer Creates On Line Label Superstore Catering To Users Of Blank Labels For Thermal Printers 58739 2Major Central Florida Label Printer Creates On Line Label Superstore Catering To Users Of Blank Labels For Thermal Printers 58739 3Your Eyes May Help Diagnose Heart Disease and Stroke 58736 1Your Eyes May Help Diagnose Heart Disease and Stroke 58736 2Your Eyes May Help Diagnose Heart Disease and Stroke 58736 3
...., May 5 Vaccines don,t just keep children,health... who can earn,higher wages and save more money, ac...t the Harvard School of Public Health., Bloom, wh...n developing,countries, will be the keynote speake...h sponsored by the National Foundation for Infecti...
...o., May 5 N30 Pharma (N30), a,biopharmaceutical c...commercialization of drugs that target endogenous ...sfully completed Phase I study of N30-201,in patie...hy volunteers.,N30 intends to develop N30-201 for ...iseases, including Cystic Fibrosis and asthma., "...
Other Medicine Technology:Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 2Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 3Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 4Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 5Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 6N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201 2
...aocular membranes in vitreoretinal surgery, to vis...aneblue in an air-filled vitreous cavity, the intr... dye. After removal of all excess dye under air, t...hed from the underlying, unstained retina after re...
Rhex ID
Autorefractometer Accuref 8001
Palm-ARK
Medicine Products: